<DOC>
	<DOCNO>NCT01157013</DOCNO>
	<brief_summary>Positron emission tomography ( PET ) [ 18F ] fluorodeoxyglucose ( FDG-PET ) evaluate cancer cell glycolysis ( Warburg effect ) surrogate tumor response.The hypothesis study early change FDG-PET signal predict sorafenib response hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Role Positron Emission Tomography Evaluation Response Sorafenib Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) major health issue worldwide , particularly Asia Africa , disease increase incidence Western world past 20 year primarily result prevalence hepatitis C virus infection , predispose patient HCC . Sorafenib ( new oral potent multikinase inhibitor direct tumour proliferation angiogenesis ) consider standard care patient advance metastatic HCC candidate curative locoregional therapy . Clinical benefit show 75 % patient advanced HCC . PET noninvasive imaging technique might effective tool evaluate sorafenib treatment HCC . The aim study evaluate new treatment PET fluorodeoxyglucose ( FDG ) , since use compute tomography ( CT ) measurement question . Our hypothesis early effect sorafenib treatment advanced HCC detect quantify PET-CT one month treatment . We try reveal decrease tumour glucose uptake one month correlate radiologic finding ( measure CT diffusion-weighted nuclear resonance image ) clinically relevant endpoint clinical benefit overall survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>advanced hepatocellular carcinoma : diagnostic assessment biopsy/cytology ; cirrhotic patient conventional radiologic criterion also accept 18 year age . life expectancy great three month candidate sorafenib therapy inform consent require hepatocellular carcinoma patient candidate local/curative therapy ( surgery/radiofrequency/TACE/other local therapy another active cancer primary liver cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Response Evaluation</keyword>
</DOC>